Business · 1 sources covering this

Divi's Laboratories Q2 Review: Goldman Sachs, Jefferies, JPMorgan Raise Target Prices; Kotak Maintains Sell

Jefferies raised its target price on Divi’s Laboratories to Rs 12,550, citing upcoming CDMO commercialisation, peptide opportunities, and stronger growth prospects.

Share:WhatsApp X Reddit Facebook LinkedIn

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

NDTVCenter·2h ago
Divi's Laboratories Q2 Review: Goldman Sachs, Jefferies, JPMorgan Raise Target Prices; Kotak Maintains Sell
Jefferies raised its target price on Divi’s Laboratories to Rs 12,550, citing upcoming CDMO commercialisation, peptide opportunities, and stronger growth prospects.
Read at NDTV →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://hindustansphere.com/embed/cluster/a9bbc23f0ecf09fd085d387cc8e76402b0928a6e"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Divi's Laboratories Q2 Review: Goldman Sachs, Jefferies, JPMorgan Raise Target Prices; Kotak Maintains Sell"></iframe>

Divi's Laboratories Q2 Review: Goldman Sachs, Jefferies, JPMorgan Raise Target Prices; Kotak Maintains Sell

How 1 sources are covering this

Divi's Laboratories Q2 Review: Goldman Sachs, Jefferies, JPMorgan Raise Target Prices; Kotak Maintains Sell

More from Business

Fermin stars as Barcelona come from behind to defeat Atletico Madrid 2-1

Bank holiday today: Are banks open or closed on November 9? Check details

Man United stage late comeback to hold Aston Villa 4-4 at Old Trafford

Rupee extends winning streak, breaks below 94 against dollar: What's next

Reader

Trust & legal

Across the network